Contemporary OB/GYN week in review: mifepristone, bacterial vaginosis, and more
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Contemporary OB/GYN week in review: mifepristone, bacterial vaginosis, and more
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, February 26 - Friday, March 01 2024), and click each link to read and watch anything you may have missed.
1.) Walgreens and CVS to distribute mifepristone
Walgreens and CVS pharmacies are set to dispense mifepristone in select states, aiming to address legal complexities and enhance accessibility amidst ongoing regulatory and legal battles.
Click here for the full article.
2.) Demystifying bacterial vaginosis: Understanding, treatment, and breaking stigmas
Misunderstandings surrounding bacterial vaginosis can delay treatment, but advancements such as XACIATO offer effective solutions, emphasizing the importance of open communication and continued research for comprehensive women's health care.
Click here for the full article.
3.) Unveiling metabolic markers of Candida albicans infection
Discover how metabolomics sheds light on potential biomarkers for early detection and treatment of Candida albicans-induced vulvovaginal candidiasis, offering crucial insights into the pathogenesis of this prevalent inflammatory condition.
Click here for the full article.
4.) 6 Strategies to Improve Antenatal HIV, HBV, Syphilis Screening
A recent systematic review highlighted a half-dozen methods to improve antenatal STI screening in low- and middle-income countries in need of better options.
Click here for the full article.
5.) Placental oxygenation's link to fetal brain volumes
Discover how transverse relaxation time mapping, a sensitive magnetic resonance imaging-based technique, unveils the relationship between placental oxygenation and fetal brain development, shedding light on potential biomarkers for assessing fetal well-being.
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
